Literature DB >> 16270720

Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit.

James H Day1, Maureen P Briscoe, Elizabeth Rafeiro, Jodan D Ratz, Anne K Ellis, Charles W Frankish, Douglass Chapman, Emilio C deGuia, Benjamin Kramer, Christopher Warner.   

Abstract

In a previous study, cetirizine and fexofenadine similarly relieved seasonal allergic rhinitis symptoms in the first 5 hours, but cetirizine was more effective at 21-24 hours postdose. This randomized, double-blind, placebo-controlled study compared the response to treatment between 5 and 12 hours. Eligible ragweed allergic subjects were exposed to pollen in the Environmental Exposure Unit and randomized (n = 599) to a single dose of cetirizine, 10 mg; fexofenadine, 180 mg; or placebo (2.5:2.5:1). The primary efficacy end point was the change from baseline in total symptom severity complex (TSSC) score at 12 hours postdose. TSSC score was the sum of self-rated scores (0 = absent to 3 = severe) for runny nose, sneezing, itchy nose/palate/throat, and itchy/watery eyes, recorded half-hourly. Mean baseline TSSC scores were similar: 9.2, cetirizine and fexofenadine; 8.9, placebo. Reductions in TSSC scores from baseline were 4.3 at 12 hours and 5.0 overall (i.e., average over 5-12 hours postdose) for cetirizine and 3.4 and 4.4, respectively, for fexofenadine. Cetirizine produced a 26% greater reduction in TSSC at 12 hours (p = 0.001) and 14% greater reduction in TSSC overall (p = 0.006) compared with fexofenadine. Cetirizine and fexofenadine reduced TSSC scores (p < 0.001) and individual symptoms (p < 0.05) more than placebo. However, cetirizine was more effective than fexofenadine (p < 0.05) for runny nose and sneezing (12 hours and overall), itchy/watery eyes (12 hours), and itchy nose/throat/palate (overall). Incidence of treatment-emergent adverse events and somnolence were similar among groups: cetirizine, 25.3 and 0.8%, respectively; fexofenadine, 29.6 and 0%, respectively; placebo, 35.0 and 0%, respectively. In conclusion, cetirizine produced greater relief of seasonal allergic rhinitis symptoms than fexofenadine at 12 hours postdose and over the 5- to 12-hour postdose period.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16270720

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  8 in total

1.  Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy.

Authors:  Lawrence DuBuske; Krzysztof Kowal
Journal:  Curr Allergy Asthma Rep       Date:  2009-03       Impact factor: 4.806

Review 2.  Controlled Allergen Challenge Facilities and Their Unique Contributions to Allergic Rhinitis Research.

Authors:  Michelle L North; Mena Soliman; Terry Walker; Lisa M Steacy; Anne K Ellis
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

Review 3.  Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Authors:  Philippe Devillier; Nicolas Roche; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 4.  Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.

Authors:  Claus Bachert; Marcus Maurer
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

5.  Clinical validation of controlled grass pollen challenge in the Environmental Exposure Unit (EEU).

Authors:  Anne K Ellis; Lisa M Steacy; Barnaby Hobsbawn; Caroline E Conway; Terry Jb Walker
Journal:  Allergy Asthma Clin Immunol       Date:  2015-01-27       Impact factor: 3.406

Review 6.  Towards definitive management of allergic rhinitis: best use of new and established therapies.

Authors:  Lubnaa Hossenbaccus; Sophia Linton; Sarah Garvey; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2020-05-27       Impact factor: 3.406

7.  A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis.

Authors:  Anne K Ellis; Yifei Zhu; Lisa M Steacy; Terry Walker; James H Day
Journal:  Allergy Asthma Clin Immunol       Date:  2013-05-01       Impact factor: 3.406

8.  Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.

Authors:  Cheng-Zhi Huang; Zhi-Hui Jiang; Jian Wang; Yue Luo; Hua Peng
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-29       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.